Clinical trials: Mild to Moderate Asthma
Asthma
Single and Multiple Ascending Dose Study of TD-8236 by Inhalation
This is a Phase 1, randomized, double-blinded, placebo controlled study. The study consists of 3 parts: Part A is a single ascending dose (SAD) study in healthy subjects, Part B is a multiple ascending dose (MAD) study in…
- Trial name
- NCT03652038
- Testing
- TD-8236
- Where
- 2 sites in United Kingdom
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- Theravance Biopharma
Asthma
Efficacy of Ciclesonide Versus Placebo Administered Either as Once Daily or Twice Daily in Patients Treated Previously With an Inhaled Corticosteroid
To investigate the efficacy of ciclesonide MDI either as once daily or a twice daily regimen in patients with mild to moderate asthma, who have previously been treated with an inhaled corticosteroid.
- Trial name
- NCT00174733
- Testing
- Ciclesonide (XRP1526)
- Where
- United States
- Volunteers
- 456 people
- Sponsor
- Sanofi
Asthma
Efficacy and Tolerability of Maintenance Treatment With Asmanex Twisthaler Versus Placebo in Mild/Moderate Persistent Asthmatics (Study P04654)(TERMINATED)
This is a randomized, multicenter, placebo-controlled, double-blind, parallel-group study evaluating Asmanex Twisthaler 220 mcg once daily (QD) in the evening (PM) compared with "Asmanex" Placebo QD PM for 12 weeks.
- Trial name
- NCT00442351
- Testing
- Asmanex twisthaler
- Volunteers
- 26 people
- Sponsor
- Organon and Co
Asthma
To Compare the Safety, Tolerability, and Pharmacokinetics of QBX258 in Patients With Asthma
This study is designed to compare the safety, tolerability, and pharmacokinetics of QBX258 (sequential administration of a fixed dose of VAK694 and single ascending doses of QAX576) in patients with well-controlled mild to…
- Trial name
- NCT01568762
- Testing
- VAK694, QAX576
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Novartis Pharmaceuticals
Mild or Moderate Asthma
Gemini Symbicort pMDI
The purpose of this study is to determine whether treatment with Symbicort for 12 weeks will improve lung function and symptoms of adults and adolescents with asthma.
- Trial name
- NCT00646516
- Testing
- budesonide/formoterol (Symbicort)
- Volunteers
- 615 people
- Sponsor
- AstraZeneca
Allergic Asthma
The Tolerability and Effects of AZD8848 in Allergic Asthma Subjects Challenged With Inhaled Allergen
AZD8848 is a new drug that is being tested for the treatment of asthma and allergic rhinitis (hayfever). This study will be in two parts and will include 59 asthmatic patients in total.
- Trial name
- NCT00999466
- Testing
- AZD8848
- Where
- 2 sites in United Kingdom
- Volunteers
- 60 people
- Sponsor
- AstraZeneca
Asthma
Single-dose Crossover Study to Compare the Safety and Efficacy of FlutiForm With Fluticasone and Formoterol Concurrently or Alone in Asthma Patients
The primary purpose was to evaluate the efficacy of SKP FlutiForm HFA MDI compared to placebo or fluticasone and formoterol administered concurrently or alone in asthma patients.
- Trial name
- NCT00830102
- Testing
- fluticasone propionate, formoterol fumarate
- Where
- 6 sites in Ireland, United Kingdom
- Volunteers
- 64 people
- Sponsor
- SkyePharma AG
Asthma
Efficacy and Safety of Fexofenadine in Mild to Moderate Persistent Asthma
The purpose of this study is to investigate the efficacy and safety of fexofenadine 120mg BID compared to placebo in the treatment of subjects with mild to moderate persistent asthma
- Trial name
- NCT00044824
- Testing
- Fexofenadine
- Where
- 7 sites in United States, Costa Rica and 5 more
- Volunteers
- 1,000 people
- Sponsor
- Sanofi
Asthma
Clinical Endpoint Trial Investigating Once Daily and Bronchodilator Dosing
Subjects will attend the unit for out-patient visits on Day 1, Day 7, Day 14 and Day 15 of each treatment period. The washout period between each treatment period will be a minimum of 10 days and maximum of 28 days.
- Trial name
- NCT00549744
- Testing
- GSK256066
- Where
- 3 sites in New Zealand, South Africa
- Volunteers
- 78 people
- Sponsor
- GlaxoSmithKline
Asthma
A Two-week Study Assessing the Onset of Effect Questionnaire Administered Pre-dose Versus Post-dose in Adult Subjects
The purpose of this study is to demonstrate whether subjects respond similarly to the Onset of Effect Questionnaire (OEQ) administered pre-dose versus post-dose, while receiving SYMBICORT® pMDI 80/4.5 μg x 2 actuations twice…
- Trial name
- NCT00449501
- Testing
- Budesonide/formoterol pMDI, Budesonide HFA pMDI
- Where
- 46 sites in United States
- Volunteers
- 134 people
- Sponsor
- AstraZeneca
Healthy Participants, Asthma
A First-in-human, Single-ascending-dose Study of IBI3002 in Healthy Participants and Mild to Moderate Asthmatics
This is a single-center, randomized, double-blind, placebo-controlled, phase 1, single-ascending-dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of IBI3002 in healthy participants…
- Trial name
- NCT06213844
- Testing
- IBI3002
- Where
- Australia
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Asthma
A Comparison of Critical Errors, Overall Errors, Training/Teaching Time, and Preference Attributes of the ELLIPTA Versus BREEZHALER Dry Powder Inhalers (DPIs) in Adult Participants With Asthma
This study aims to provide data in adult participants with mild to moderate asthma to assist healthcare professionals (HCPs) in assessing various attributes of ELLIPTA and BREEZHALER DPIs, by comparing the incidence of critical…
- Trial name
- NCT04813354
- Testing
- ELLIPTA, BREEZHALER
- Where
- 3 sites in Netherlands
- Volunteers
- 114 people
- Sponsor
- GlaxoSmithKline
Asthma
Beclomethasone Dipropionate HFA in Adult and Adolescent Subjects With Mild to Moderate Persistent Asthma
Approximately 480 (120 per group) would need to complete the 12 weeks of treatments.
- Trial name
- NCT03835871
- Testing
- 400 µg per day Beclomethasone, 200 µg per day Beclomethasone, 100 µg per day Beclomethasone
- Sponsor
- Adamis Pharmaceuticals Corporation
Asthma COPD
Single and Multiple Ascending Dose Study of KN-002
This is a Phase 1, randomized, double-blinded, placebo controlled study. The study consists of 4 parts: Part 1 is a single ascending dose (SAD) study in healthy volunteers; Part 2 is a multiple ascending dose (MAD) study in…
- Trial name
- KN-002 (NCT05006521)
- Testing
- KN-002
- Where
- United Kingdom
- Volunteers
- 117 people, healthy volunteers welcome
- Sponsor
- Kinaset Therapeutics Inc
Asthma
Study to Evaluate the Efficacy and Safety of Benralizumab in Adult Patients With Mild to Moderate Persistent Asthma
The purpose of this trial is to confirm the safety and clinical benefit of benralizumab administration in asthma patients with mild to moderate persistent asthma in order to gain an understanding of the benefit/risk of…
- Trial name
- NCT02322775
- Testing
- Benralizumab
- Where
- 57 sites in United States, Canada and 4 more
- Volunteers
- 211 people
- Sponsor
- AstraZeneca
Migraine
A Study of the Pulmonary Safety and Pharmacokinetics of Zolmitriptan Inhalation Powder
This study is an open-label, parallel group study to evaluate acute pulmonary safety and Pharmacokinetics (PK) of two doses, separated by 2 hours, of CVT-427 zolmitriptan inhalation powder in three groups of adults: those with…
- Trial name
- NCT02905227
- Testing
- CVT-427 (zolmitriptan inhalation powder)
- Where
- 3 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Acorda Therapeutics
Asthma
Safety, Tolerability, and Pharcodynamics of AMG 853 in Adolescents With Asthma
The purpose of this study is to study the safety and tolerability in adolescent and adult subjects with intermittent or mild to moderate persistent asthma.
- Trial name
- NCT01137565
- Testing
- AMG 853
- Volunteers
- 23 people
- Sponsor
- Amgen
Asthma, Allergic Rhinitis
A Study to Compare Effectiveness of Montelukast Sodium With Comparator in Mild to Moderate Persistent Asthmatics (0476-329)
Subjects have 8-week with montelukast sodium or comparator drug administration period, 2-week wash-out period and 8-week comparator drug or the drug administration period (with cross-over design) for assessment of the drug…
- Trial name
- NCT00157937
- Testing
- MK0476; montelukast sodium/Duration of Treatment: 16 weeks, Comparator: theophylline ER/Duration of Treatment: 16 weeks
- Volunteers
- 31 people
- Sponsor
- Organon and Co
Asthma
Chronic Dosing Cross-Over Study to Assess the Efficacy and Safety of Glycopyrronium (PT001) in Adult Subjects With Intermittent Asthma or Mild to Moderate Persistent Asthma
A Randomized, Double-Blind, Chronic Dosing (14 days), 5-Period, 7-Treatment, Placebo-Controlled, Incomplete Block, Cross-Over, Multi-center, Dose-ranging Study to Assess the Efficacy and Safety of Glycopyrronium MDI (PT001)…
- Trial name
- NCT02433834
- Testing
- Glycopyrronium MDI, Serevent Diskus 50 μg
- Where
- 43 sites in United States
- Volunteers
- 248 people
- Sponsor
- Pearl Therapeutics, Inc.
Asthma
Albuterol DPI (A006) Clinical Study-B3:Efficacy, Dose-ranging and Safety Evaluation
This study evaluates the efficacy, dose-ranging and safety profiles of A006, an Albuterol dry powder inhaler (DPI), in the dose range of 110 to 220 mcg per dose in comparison to a DPI Placebo Control and an Albuterol metered dose…
- Trial name
- A006-B3 (NCT02210806)
- Testing
- A006 DPI, Proventil® MDI
- Where
- 4 sites in United States
- Volunteers
- 22 people
- Sponsor
- Amphastar Pharmaceuticals, Inc.